In Brief: Fountain Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
Fountain Pharmaceuticals: Has entered into a long-term licensing and supply agreement with Dermik Labs for products using Fountain's encapsulation delivery system, the company announced Jan. 19. Collegetown, Penn.-based Dermik, a subsidiary of Rhone-Poulenc Rorer, currently markets Hytone hydrocortisone cream, Zetar coal tar shampoo, and Shepard's cream lotion, while Fountain is mostly involved in moisturizers and sunscreens. The companies plan to begin introducing new products domestically and internationally within the next few months under the agreement...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning